INHIBRX BIOSCIENCES, INC. Proceeds from Stock Options Exercised
INHIBRX BIOSCIENCES, INC. (INBX) reported Proceeds from Stock Options Exercised of $2.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. proceeds from stock options exercised for the quarter ending 2026-06-30 was $1.60M.
- INHIBRX BIOSCIENCES, INC. proceeds from stock options exercised for the quarter ending 2026-03-31 was $471.00K.
- INHIBRX BIOSCIENCES, INC. proceeds from stock options exercised for the quarter ending 2025-12-31 was $1.25M.
- INHIBRX BIOSCIENCES, INC. proceeds from stock options exercised for the quarter ending 2025-09-30 was $352.00K.
- INHIBRX BIOSCIENCES, INC. proceeds from stock options exercised for fiscal 2025 was $1.61M, a 97.76% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. proceeds from stock options exercised for fiscal 2024 was $71.68M, a 2994.91% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. proceeds from stock options exercised for fiscal 2023 was $2.32M.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.08M 10-Q · filed 2026-08-13 | $3.33M derived: sum of 3 quarters · filed 2026-08-13 | $3.68M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $471.00K 10-Q · filed 2026-05-14 | $1.73M derived: sum of 2 quarters · filed 2026-05-14 | $2.08M derived: sum of 3 quarters · filed 2026-05-14 | $2.08M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.61M derived: sum of 2 quarters · filed 2026-03-19 | $1.61M derived: sum of 3 quarters · filed 2026-08-13 | $1.61M 10-K · filed 2026-03-19 |
| 2025-09-30 | $352.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $352.00K derived: sum of 2 quarters · filed 2026-08-13 | $352.00K 10-Q · filed 2025-11-14 | $352.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $0.00 derived: sum of 2 quarters · filed 2026-05-14 | $0.00 derived: sum of 3 quarters · filed 2026-05-14 | $32.95M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $32.95M derived: sum of 3 quarters · filed 2026-03-19 | $71.68M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $32.95M derived: sum of 2 quarters · filed 2025-11-14 | $71.68M 10-Q · filed 2025-11-14 | $72.76M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $32.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $71.68M 10-Q · filed 2025-08-13 | $72.76M derived: sum of 3 quarters · filed 2025-08-13 | $72.78M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $38.73M 10-Q · filed 2025-05-14 | $39.81M derived: sum of 2 quarters · filed 2025-05-14 | $39.83M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.11M derived: sum of 2 quarters · filed 2025-03-17 | $2.32M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.23M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $1.21M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |